TSHA president sells shares to cover RSU taxes

Taysha Gene Therapies President and Head of R&D Nagendran Sukumar reported routine share sales tied to tax withholding.

Rhea-AI Filing Summary

Taysha Gene Therapies President and Head of R&D Nagendran Sukumar reported routine share sales tied to tax withholding. On January 23, 2026, he sold 89,132 shares of common stock at a weighted average price of $4.75. On January 26, 2026, he sold an additional 26,918 shares at a weighted average price of $4.61.

According to the disclosure, these transactions were part of a mandatory sell-to-cover arrangement used solely to satisfy income tax liabilities from vesting restricted stock unit awards. After the reported sales, Sukumar beneficially owned 1,317,389 shares of Taysha Gene Therapies common stock directly.

Insider Trade Summary

Net Seller: 116,050 shares

Net Sell 2 txns

Insider Nagendran Sukumar

Role President and Head of R&D

Sold 116,050 shs ($547K)

Type	Security	Shares	Price	Value
Sale	Common Stock	26,918	$4.61	$124K
Sale	Common Stock	89,132	$4.75	$423K

Holdings After Transaction: Common Stock — 1,317,389 shares (Direct)

Footnotes (3)

1. F1. The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
2. F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
3. F3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did TSHA President Nagendran Sukumar report?

Nagendran Sukumar reported selling 89,132 shares of Taysha Gene Therapies common stock on January 23, 2026 and 26,918 shares on January 26, 2026.

At what prices were the TSHA shares sold by Nagendran Sukumar?

The 89,132 shares sold on January 23, 2026 were at a weighted average price of $4.75, and the 26,918 shares sold on January 26, 2026 were at a weighted average price of $4.61.

Why did TSHA insider Nagendran Sukumar sell these shares?

The filing states the shares were sold under a mandatory sell-to-cover arrangement to satisfy income tax liabilities incurred upon vesting of restricted stock unit awards.

How many TSHA shares does Nagendran Sukumar own after these transactions?

Following the reported transactions, Nagendran Sukumar beneficially owned 1,317,389 shares of Taysha Gene Therapies common stock directly.

What is Nagendran Sukumar’s role at Taysha Gene Therapies (TSHA)?

Nagendran Sukumar is a Director and serves as President and Head of R&D at Taysha Gene Therapies.

Were the TSHA share sales by Nagendran Sukumar discretionary or plan-based?

The disclosure describes the sales as pursuant to a mandatory sell-to-cover arrangement connected to tax withholding on vesting RSU awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/27/2026 - 04:05 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nagendran Sukumar

(Last) (First) (Middle)

C/O TAYSHA GENE THERAPIES, INC.

3000 PEGASUS PARK DRIVE, SUITE 1430

(Street)

DALLAS TX 75247

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Taysha Gene Therapies, Inc. [ TSHA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and Head of R&D

3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/23/2026		S		89,132(1)	D	$4.75(2)	1,344,307	D
Common Stock	01/26/2026		S		26,918(1)	D	$4.61(3)	1,317,389	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).

3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive.

	/s/ Kamran Alam, Attorney-in-Fact	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.